Viewpoints: Two views of Medicare equipment bidding changes; High Court case may impact FDA approval process

Published on March 19, 2013 at 3:24 AM · No Comments

USA Today: Medicare Bidding Competition In Danger: Our View
In 2010, Medicare spent more than $14 billion on oxygen devices, mobility scooters, diabetes test strips and other "durable medical equipment" and supplies that patients use at home. For taxpayers, and for beneficiaries with a 20% co-pay, that was about $5 billion too much. Everyone overpaid because for years, Medicare bought or rented things like this on a fee schedule set by Congress, for prices that had nothing to do with normal market competition (3/18).

USA Today: Fix The Sham Bidding Program: Opposing View
In 2003, Congress required Medicare to ensure that medical equipment and supplies used by beneficiaries at home (known as "durable medical equipment," or DME) are procured through a system that increases competition and achieves market-based prices, but doesn't diminish quality. Unfortunately, Medicare has completely mismanaged the design and implementation of its bidding program for home oxygen equipment, power wheelchairs, diabetic supplies and other critical home medical products (Tyler J. Wilson, 3/18).

The New York Times: Drugs For Early Stage Alzheimer's
The Food and Drug Administration has proposed lowering the bar for approving drugs to treat people at the earliest stages of Alzheimer's disease, before they have developed any serious impairment or overt dementia. The goal is commendable -; to find ways to prevent or slow the progression of this terrible disease before it can rob people of their mental capacities. But the proposal raises troubling questions as to whether the agency would end up approving drugs that provide little or no clinical benefit yet cause harmful side effects in people who take the medications for extended periods (3/17). 

Los Angeles Times: Battle Over 'Biosimilars'
One of the most promising frontiers in healthcare is biologic medicines -; complex substances derived from living cells that can help fight chronic diseases and cancers. To encourage investment in biologics, Congress in 2010 gave drug companies what amounts to a 12-year monopoly on the substances they developed. Now, supporters of biologics are pushing lawmakers in Sacramento and other state capitals to put new hurdles in the way of knock-off compounds, called "biosimilars" (3/17). 

Politico: Court Case Could Undermine Drug Approval Process
On Tuesday, the Supreme Court will weigh a novel legal theory being advanced by the trial bar that, if upheld, could become the torts' next big payday against drugmakers. The case could also undermine the basic tenets of the Food and Drug Administration's process for approving new medicines. For this latter reason, the trial bar finds itself on the other side of the Obama administration, which has filed an amicus brief in the case (Scott Gottlieb, 3/17).

The New York Times: The Real Spending Problem
[T]he taxes-versus-spending distinction is largely meaningless. Each year, the government doles out tax breaks worth $1.1 trillion. That is more than the cost of Medicare and Medicaid combined. ... Yet in budget talks, Republicans ignore tax entitlements, which flow mostly to high-income taxpayers, while pushing to cut Medicare, Medicaid and Social Security (3/16).

The Washington Post: America The Retirement Home
The budget debate' central reality is that federal retirement programs, led by Social Security and Medicare, are crowding out most other government spending. Until we openly recognize and discuss this, it will be impossible to have a "balanced approach" -; to use one of President Obama's favorite phrases. It's the math: In fiscal 2012, Social Security, Medicare, Medicaid and civil service and military retirement cost $1.7 trillion, about half the budget (Robert J. Samuelson, 3/17).

Reuters: 2014: The Democrats' Dilemma
Obama continues to seek a "grand bargain," reiterating his willingness to cut Medicare and Social Security in exchange for Republican acceptance of greater revenue – largely from closing loopholes. Entrenched Republican opposition to any tax increase has thus far saved the country and the president from any deal. But the president's very public pursuit makes more and more Americans aware of the proposed terms. Republicans show their base that they are standing staunch against any further tax hikes, while pushing hard to slash spending. In contrast, the president suggests to his base that he is open to abandoning the commitment to defend Social Security and Medicare if the price is right (Robert L. Borosage, 3/18).

The Medicare NewsGroup: The Potent Opposition To Medicare's Proposal For Greater Drug Rebates
One of the largest potential savings Medicare could reap is from drug costs, and that would come from asking drug companies for bigger rebates. Medicaid and the Veteran's Administration each demand steep discounts as single payers, as do most governments with national health programs. But Medicare is unlikely to get similar huge markdowns from drug companies and middlemen anytime soon because the proposal faces a torrent of opposition from the pharmaceutical lobby and legislators allied with it (John Wasik, 3/15).

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment